Giving away HIV drugs is not as easy as it seems.
When officials with Boehringer ingelheim announced in July 2000 that the company would make its HIV antiretroviral drug nevirapine (Viramune) available to any pregnant women in sub-Saharan Africa who need it for the prevention of mother-to-child transmission of HIV, they thought their biggest problem would be to meet the flood of demand. They were wrong. Why has demand been so low?